Clinical Trial Update: Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating guselkumab in active psoriatic arthritis patients with inadequate response/intolerance to one prior anti-TNF agent.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Arthritis Psoriatic
• Psoriatic Arthritis

Drugs mentioned

• Guselkumab (guselkumab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Arthritis, Psoriatic | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-12-08